{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:43:57Z","timestamp":1791150237748,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.lungcan.2018.09.015","type":"journal-article","created":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T16:36:58Z","timestamp":1537288618000},"page":"150-156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":184,"special_numbering":"C","title":["Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer"],"prefix":"10.1016","volume":"125","author":[{"given":"Jun Yeun","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junghoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Joo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6943-4462","authenticated-orcid":false,"given":"Young-Jae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Il","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8030-3332","authenticated-orcid":false,"given":"Choon-Taek","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Sun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18_suppl","key":"10.1016\/j.lungcan.2018.09.015_bib0005","doi-asserted-by":"crossref","first-page":"7082","DOI":"10.1200\/jco.2006.24.18_suppl.7082","article-title":"Temporal trends in small cell lung cancer: analysis of the national surveillance, epidemiology, and end-results (SEER) database","volume":"24","author":"Navada","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.lungcan.2018.09.015_bib0010","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.lungcan.2018.09.015_bib0015","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non\u2013small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2018.09.015_bib0020","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol."},{"issue":"17","key":"10.1016\/j.lungcan.2018.09.015_bib0025","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2018.09.015_bib0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.lungcan.2018.09.015_bib0035","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.lungcan.2018.09.015_bib0040","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti\u2013programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non\u2013small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2018.09.015_bib0045","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol."},{"issue":"10027","key":"10.1016\/j.lungcan.2018.09.015_bib0050","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.lungcan.2018.09.015_bib0055","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.lungcan.2018.09.015_bib0060","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti\u2013programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2018.09.015_bib0065","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.lungcan.2018.09.015_bib0070","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"03","key":"10.1016\/j.lungcan.2018.09.015_bib0075","article-title":"Common terminology criteria for adverse events (CTCAE) version 4.0","volume":"4","author":"U.D.o. Health","year":"2009","journal-title":"Natl. Inst. Health Natl. Cancer Inst."},{"issue":"35","key":"10.1016\/j.lungcan.2018.09.015_bib0080","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","article-title":"Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)","volume":"35","author":"Horn","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2018.09.015_bib0085","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report","volume":"194","author":"Collard","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.lungcan.2018.09.015_bib0090","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2018.09.015_bib0095","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1164\/rccm.201704-0795OC","article-title":"Chronic obstructive pulmonary disease alters immune cell composition and immune checkpoint inhibitor efficacy in non\u2013small cell lung cancer","volume":"197","author":"Mark","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"12","key":"10.1016\/j.lungcan.2018.09.015_bib0100","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced Cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2018.09.015_bib0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12890-018-0592-x","article-title":"High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review","volume":"18","author":"Koyama","year":"2018","journal-title":"BMC Pulm. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2018.09.015_bib0110","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","article-title":"Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study","volume":"177","author":"Kudoh","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218305749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218305749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T21:13:08Z","timestamp":1662066788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500218305749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":22,"alternative-id":["S0169500218305749"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.09.015","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}